| P/E (FY) | — | Sales (TTM) | $8.1M |
| Earnings (TTM) | -$99.7M | ROE | −75.99% |
| Net Margin | −1218.45% | ROIC | −160.20% |
| Debt / Equity | 0.40 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $370.7M | Trading Days | 2178 |
| 52W High | 4.83 |
| 52W Low | 1.35 |
| % Off High | −18.63% |
| YTD | −1.75% | 1Y | 84.51% |
| 3Y | −92.83% | 5Y | −97.76% |
| Since incept. (ann.) | −52.50% |
Reportable 100%
| Ann. Volatility (1Y) | 121.98% | Ann. Volatility (3Y) | 125.32% |
| Sharpe (1Y) | 1.02 | Sharpe (3Y) | −0.09 |
| Max Drawdown (1Y) | −37.55% | Max Drawdown (3Y) | −97.41% |
| Beta (3Y, vs SPY) | 0.47 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| IPSC | Century Therapeutics, Inc. | $369.7M | — |
| CMPX | Compass Therapeutics, Inc. | $367.4M | — |
| AUTL | Autolus Therapeutics plc | $385.9M | — |
| PALI | PALISADE BIO, INC. | $350.6M | — |
| CCCC | C4 Therapeutics, Inc. | $392.5M | — |
| STRO | SUTRO BIOPHARMA, INC. | $393.2M | — |
| FENC | FENNEC PHARMACEUTICALS INC. | $345.3M | — |
| LXEO | Lexeo Therapeutics, Inc. | $344.7M | — |
| OCGN | Ocugen, Inc. | $419.8M | — |
| DNA | Ginkgo Bioworks Holdings, Inc. | $427.0M | — |
| CABA | Cabaletta Bio, Inc. |
| $445.1M |
| — |
| NMRA | Neumora Therapeutics, Inc. | $307.6M | — |
